Abstract:Objective To investigate the cross reaction characteristics of recombinant human papillomavirus 16 type L2 full-length fusion protein in HPV types of 6, 11, 18.Methods The serum samples of 108 condyloma acuminatum patients, 156 cervix cancer patients and 100 healthy control subjects were collected.The gene of full-length HPV16 L2 was amplificated from the tissue DNA of cervical cancer patient and inserted into the prokaryotic expression vector PGEX-4T-1 to construct the recombinant plasmid PGEX-4T-1-HPV16 L2.After sequencing identification, the recombinant plasmid was tranformed into E.coli BL21 (DE3).After induction by IPTG, the fusion protein containing HPV16 L2 was expressed and analyzed by both SDS-PAGE and WB.Furthermore, the specific binding capacity of the fusion protein to the HPV 6,11, 16 and 18 DNA positive patient's sera were analyzed by WB.The fusion protein was purified with NiNTA Agarose Kit and coated with ELISA reaction plates.The specific serum IgG were detected by indirect ELISA.Results The recombinant plasmid PGEX-4T-1-HPV16 L2 was constructed successfully. Highly expressed HPV16 L2 full-length fusion protein was obtained and the expression level was 27.2 %.The relative molecular mass(Mr) of the fusion protein is about 82 × 103, which matches up to the expected Mr.Meanwhile, the sera of HPV 6,11,16,18 DNA positive patients were used as the primary antibody and the Mr of the specific band was detected to be about 82 × 103 by WB.The results of indirect ELISA showed that the average levels of specific IgG in condyloma acuminatum group, cervical cancer group and healthy control subjects were 0.848 ±0.257, 0.822 ±0.247 and 0.173 ±0.143 with the positive rate of 92.6%, 94.2%and 8.0% respectively.There was no significance of the specific IgG levels between condyloma acuminatum group and cervical cancer group ( F = 0, P ＞ 0.05 ), but there was significant difference of specific IgG levels and positivity among the three groups ( F = 305.201 ,x2 = 253.178, P ＜ 0.01 ).Conclusions The HPV16 L2 full-length fusion protein has better antigenicity.However cross reactions with HPV6, 11 and 18 were found.It can be applied in serological screening reagents for HPV infection and associated cancer.

[Preparation and Identification of Type Specific and Conformation Dependent HPV16 L1 Protein Monoclonal Antibody.].

Expression and Purification of HPV58 E1 Protein and Preparation of Polyclonal Antibodies against HPV 58 E1 Protein

Preparation of a Monoclonal Antibody Against the Human Papillomavirus Type 16 E7 (HPV 16 E7 ) Protein

Construction, Expression, Purification and Identification of Chimeric HPV16 E7-L1 Virus Like Particles

[Prokaryotic Expression, Purification of Human Papillomavirus Type 16 E1 Protein and Preparation of It's Antiserum].

Screening and identification of B cell epitope within the major capsid protein L1 of HPV 52, using monoclonal antibodies

Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies

A Human Monoclonal Antibody Against HPV16 Recognizes an Immunodominant and Neutralizing Epitope Partially Overlapping with That of H16.V5.

Mapping the B Cell Epitopes Within the Major Capsid Protein L1 of Human Papillomavirus Type 16.

[Preparation and Activity Detection of Chicken Egg Yolk IgY Antibody Against Human Papillomavirus 16 Type L1 Main Capsid Protein].

[Prokaryotic Expression of HPV 16 L1 Gene and Identification of Its Immune Activity].

Epitope Clustering Analysis for Vaccine-Induced Human Antibodies in Relationship to a Panel of Murine Monoclonal Antibodies Against HPV16 Viral Capsid.

Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs

Cross Reaction Characteristics of Recombinant Fusion Protein of Human Papillomavirus 16 Type L2

Production of human papillomavirus type 16 virus-like particles and its immunogenicity]

[Study on the Frequency of Human Papillomavirus Type 6 and Type 11 Infection and L1 Gene Expression of the Virus in Biopsy Samples of Pointed Condyloma Patients].

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody

Prokaryotic Expression and Purification of Minor Capsid Protein L2 Derived from Human Papillomavirus 58 and Preparation of Monoclonal Antibody

[Establishment and Application of Human Papillomavirus Type 16 Pseudovirions Neutralization Assay].